Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28477678 | 0.90 | GABRA1 (0.48) | SIRT2PARP1CCNB2CDK1CCNB1 | |
| SCHEMBL10651902 | 0.82 | SIRT2 (0.51) | SIRT2CTSVCTSLPARP1CCNB2 | |
| SCHEMBL7060933 | 0.82 | TSHR (0.42) | SIRT2CTSLFBP1ALDH1A1LMNA | |
| SCHEMBL5125095 | 0.82 | MEN1 (0.45) | FBP1ALDH1A1LMNAGAADYRK1A | |
| SCHEMBL10642510 | 0.82 | GLI1 (0.43) | FBP1ALDH1A1LMNAKDM4EGLA | |
| SCHEMBL7058105 | 0.82 | ALDH1A1 (0.45) | SIRT2CTSVCTSLFBP1ALDH1A1 | |
| SCHEMBL7064339 | 0.82 | ALDH1A1 (0.45) | CTSLFBP1ALDH1A1LMNAKDM4E | |
| SCHEMBL10643541 | 0.80 | GRIN2D (0.49) | PARP1CDK2FBP1ALDH1A1PBRM1 | |
| SCHEMBL13526650 | 0.80 | SIRT2 (0.46) | SIRT2CTSVCTSLPARP1FBP1 | |
| SCHEMBL10645311 | 0.79 | MAPT (0.44) | SIRT2CTSVCTSLFBP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202349-B2 | Asymmetric bis-acridines with antitumour activity and their uses | Gdansk University of Technology (PL) | 2019-02-12 | — | — | US | disclosed |
| US-20180086712-A1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES | Gdansk University of Technology (PL) | 2018-03-29 | — | — | US | disclosed |
| EP-3070078-B1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOR ACTIVITY AND USE THEREOF | POLITECHNIKA GDANSKA (PL) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016150799-A1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES | Politechnika Gdańska (PL) | 2016-09-29 | — | — | WO | disclosed |
| EP-3070078-A1 | Unsymetrical bisacridines with antitumor activity and use thereof | Politechnika Gdanska (PL) | 2016-09-21 | — | — | EP | disclosed |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | XANTHUS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
| US-6541483-B2 | Bisimidazoacridones, bistriazoloacridones and hybrids having both moieties; HIV | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-04-01 | — | — | US | disclosed |
| EP-0892801-B1 | ACRIDONE-DERIVED COMPOUNDS USEFUL AS ANTINEOPLASTIC AND ANTIRETROVIRAL AGENTS | US GOV HEALTH & HUMAN SERV (US) | 2002-01-02 | — | — | EP | disclosed |
| US-20010009914-A1 | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | MICHEJDA CHRISTOPHER J (US) | 2001-07-26 | — | — | US | disclosed |
| EP-0750612-A1 | ACRIDONE-DERIVED BISINTERCALATORS AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995025093-A1 | ACRIDONE-DERIVED BISINTERCALATORS AS CHEMOTHERAPEUTIC AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-21 | — | — | WO | disclosed |
| EP-0145226-B1 | SUBSTITUTED 1-AMINO-4-NITRO-ACRIDINONES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0138302-B1 | PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4626540-A | Substituted 1-amino-4-nitro-acridinones and methods of treating bacterial infections and leukemia with them | WARNER-LAMBERT COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
| US-4621086-A | Method of treating leukemia with pyrazolo[3,4,5-kl]acridines | WARNER-LAMBERT COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4588730-A | Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials | WARNER-LAMBERT COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4555572-A | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0145226-A2 | Substituted 1-amino-4-nitro-acridinones, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-06-19 | — | — | EP | disclosed |
| EP-0138302-A1 | Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009914-A1 | Acridone-derived compounds useful as antineoplastic and antiretroviral agents | EIF2AK2, SAMHD1, ZC3HAV1 | SIRT2 1788/4885CTSV 1623/4885CTSL 2764/4885 |
| US-10202349-B2 | Asymmetric bis-acridines with antitumour activity and their uses | MCL1, BAD, ACR | SIRT2 1894/4885CTSV 2408/4885CTSL 3528/4885 |
| US-20100016300-A1 | Imidazoacridine Compounds for Treating FLT3-Mediated Disorders | FLT3, CSF3R, ABL1 | SIRT2 2179/4885CTSV 2981/4885CTSL 1526/4885 |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | SIRT2 4050/4885CTSV 4098/4885CTSL 2970/4885 |
| US-20180086712-A1 | ASYMMETRIC BIS-ACRIDINES WITH ANTITUMOUR ACTIVITY AND THEIR USES | MCL1, ACR, BAD | SIRT2 2347/4885CTSV 2531/4885CTSL 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.